Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 06, 2024
A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 19, 2023
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer.
Journal: ESMO open
Published: January 10, 2020
A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies.
Journal: Oncotarget
Published: November 11, 2019
Phase II study of biweekly carboplatin, gemcitabine, and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC.
Journal: American journal of clinical oncology
Published: November 01, 2012
Showing 1-7 of 7
Last Updated: 09/26/2026